Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Commentary

SARS-CoV-2 and DPP4 inhibition: Is it time to pray for Janus Bifrons?

Dario Pitocco, Linda Tartaglione, Luca Viti, Mauro Di Leo, Alfredo Pontecorvi, Salvatore Caputo

Diabetes Care Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
Department of Endocrinology, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy

ABSTRACT

Diabetes could be a risk factor for severity and mortality in patients with coronavirus disease 2019 COVID-19. It has been hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19 infection but (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in Middle East respiratory Syndrome (MERS-CoV) (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition at present doesn’t represent a plausible approach to mitigate COVID-19.

The rapid spread of the coronavirus disease 2019 (COVID-19), caused by a zoonotic beta-coronavirus entitled SARS-CoV2, has become a global threat. According to a meta-analysis of 76,993 patients presented in 10 articles, the prevalence of diabetes among people who were infected with SARS-CoV2 was estimated to be 7.9% [1]. Diabetes could be a risk factor for severity and mortality in patients with COVID-19. A study, which included 72,314 cases of COVID-19, demonstrated that diabetic subjects had a threefold higher mortality rate than did those without diabetes (7.3% vs 2.3%) [2].

A recent commentary on Diabetes Research and Clinical Practice described the interplay between the Middle East Respiratory Syndrome (MERS-CoV), another coronavirus responsible for an outbreak of acute respiratory syndrome, and human dipeptidyl peptidase 4 (DPP4) identified as a functional receptor for virus spike protein [3]. It has been interestingly hypothesized that DPP4 inhibition, a therapy currently available for type 2 diabetes, might represent a target for decreasing the risk of the acute respiratory complications of the COVID-19, but, unfortunately, this hypothesis is on the basis of another hypothesis. To the best of our knowledge, no one has yet shown that DPP4 is a possible receptor for SARS-CoV2. On the contrary most recent data exclude this possibility, confirming that human angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV2, in analogy to SARS-CoV [4].

DPP4, like the ancient roman god Janus Bifrons (Two-Faced), is a dual and multifunctional molecule: it exists...
as soluble form (sDPP4) in the circulation [5], but also as a type II transmembrane glycoprotein located on endothelial, epithelial cells and immune cells (CD26) [6]. DPP4 in the bloodstream and at surface membrane rapidly inactivates biologically active molecules as gastrointestinal hormones, neuropeptides and chemokines, but in some cases shifts their receptor preference and thus modifies their functional activity. In addition to enzymatic cleavage, CD26 executes other multiple physiological mechanisms, as adhesion to extracellular matrix proteins, and it plays a co-stimulatory role in T-cell maturation, activation and interaction with antigen-presenting cells. Thus, DPP4 inhibition is associated with some degree of immune suppression and may be useful in some autoimmune diseases [7]. However, in most patients long-term immune suppression, albeit mild, could represent an undesirable side effect [8]. We described a case of a type 2 diabetes subject with a severe leucopenia as a consequence of DPP4 inhibitor Sitagliptin therapy [9]. In diabetic subjects treated with DPP4 inhibitors there is no increase in respiratory tract infections [10], but we want to highlight that they could produce respiratory side effects as angioedema [11], rhino-rhinitis [12], cough and dyspnea [13], as consequences of reduced degradation of bradykinin and substance P.

MERS is another example of DPP4 ambivalence. As expected, human DPP4 transgenic mice following MERS-CoV infection develop an acute inflammatory response of the lung with progressive pulmonary fibrosis [14]. However hDPP4+/− mice were more resistant than hDPP4+/− mice to MERS-CoV infection, as judged from increased LD50, reduced lung viral infection, attenuated morbidity and mortality, and reduced histopathology [15]. A possible explanation of this paradoxical protective effect of DPP4 against MERS-CoV is that the soluble DPP4 can act as a “buffer” competitively inhibiting virus entry into host cells. In fact, in human patients affected by MERS there is a reduction in circulating levels of sDPP4 with an inverse relationship with IL-10 level. In support of an antiviral effect of sDPP4, the authors demonstrated that viral infection was inhibited by 50% in the presence of more than 8000 ng/ml of sDPP4 [16]. Another aspect to consider is the possibility that MERS-CoV downregulates its receptor after the binding: dromedaries with experimental MERS show a role?. The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

In conclusion, (1) lack of demonstration of SARS-CoV2 binding to DPP4 (2) possible protective role of sDPP4 in MERS (3) demonstrated inhibition and downregulation of DPP4 by HIV1 and MERS-CoV and (4) not exclusive role of the receptor binding in tropism of the Coronavirus family, support that DPP4 inhibition does not represent a plausible approach to mitigate Covid-19.

Funding
The authors did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Arch Acad Okhuna K, Takahashi N, Yamochi T, Osono O, Dang NH, Kargili A, Karakurt F, Nur Kankilic M, Kankilic ES, Bozkurtl B. Inhibition of multifunctional dipeptodyl Hopsu-Havu VK, Glenner GG. A new dipeptide Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play Gosmanov AR, Fontentot EC. Sitagliptin-associated angioedema. Diabetes Care 2012;35 e60.

[2] Wu Z, McGoogan. Characteristic of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020. https://doi.org/10.1001/jama.2020.2648.

[3] Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role?. Diabetes Res Clin Pract 2020;162 108125.

[4] Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other betacoronaviruses. Nat Microbiol 2020;5:562–9.

[5] Hopsu-Havu VK, Glenner GG. A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide. Histochemie 1966;7:197–201.

[6] Fleischer B. CD26: a surface protease involved in T-cell activation. Immunol Today 1994;15:180–4.

[7] Okhuna K, Takahashi N, Yamochi T, Osono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008;13(2299–310):13.

[8] Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?. Diabetes Res Clin Pract 2010;88:125–31.

[9] Pitocco D, Zaccardi F, Martini F, Scavone G, Musella T, Caputo S, et al. Severe leucopenia associated with sitagliptin use. Diabetes Res Clin Pract 2011;91:e30–2.

[10] Gamble J-M, Donnan JR, Chibrikov E, Twelis LK, Midodzi WK, Majumdar SR. Comparative safety of dipeptidyl peptidase-4 inhibitors versus sulfonylureas and other glucose-lowering therapies for three acute outcomes. Sci Rep 2018;11:15142. https://doi.org/10.1038/s41598-018-33483-y.

[11] Gosmanov AR, Fontentot EC. Sitagliptin-associated angioedema. Diabetes Care 2012;35 e60.

[12] Kargili A, Karakurt F, Nur Kankilic M, Kankilic ES, Bozkurtl B. Sitagliptin intolerance. Allergol Immunopatol 2010;58:290–1.

[13] Baraniuk JN, Jamieson MJ. Rhinorrhea, cough and fatigue in patients taking sitagliptin. Allergy Asthma Clin Immunol 2010;6. https://doi.org/10.1186/1710-1492-6-8.
[14] Kim J, Yang YL, Jeong Y, Jang Y-S. Middle East Respiratory Syndrome-Coronavirus infection into established hDPP4-transgenic mice accelerates lung damage via activation of the pro-inflammatory response and pulmonary fibrosis. J Microbiol Biotechnol 2020;30:427–38.

[15] Algaissi A, Agrawal AS, Han S, Peng BH, Luo C, Li F, et al. Elevated human dipeptidyl peptidase 4 expression reduces the susceptibility of hDPP4 transgenic mice to Middle East Respiratory Syndrome Coronavirus infection and disease. J Infect Dis 2019;15:829–35.

[16] Inn K-S, Kim Y, Aigerim A, Park U, Hwang E-S, Choi M-S, et al. Reduction of soluble dipeptidyl peptidase 4 levels on plasma of patients infected with Middle East respiratory syndrome coronavirus. Virology 2018;518:324–7.

[17] Haverkamp A-K, Lehmbecker A, Spitzbarth I, Widagdo W, Haagmans BL, Segalés J, et al. Experimental infection of dromedaries with Middle East respiratory syndrome Coronavirus is accompanied by massive clariy loss and depletion of the cellsurface receptor dipeptidyl peptidase 4. Sci Rep 2018;27:9778. https://doi.org/10.1038/s41598-018-28199-2.

[18] Vaduganathan Muthiah, Vardeny Orly, Michel Thomas, McMurray John JV, Pfeffer Marc A, Solomon Scott D. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020;382(17):1653–9. https://doi.org/10.1056/NEJMoa2005760.

[19] Subramanyam M, Guthiel WG, Bachovchin WW, Huber BT. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol 1993;150:2544–53.

[20] Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020. https://doi.org/10.1016/j.bbrc.2020.02.071.